Gain-of-functional mutant p53 exhibits a longer half-life period as compared with wild-type p53, which is why the significant accumulation of the mutant p53 in cancer cells is recognized in many kinds of malignant neoplasms.
As compared with CEA and CA19-9, anti-p53 antibody (IgG subtype) can be detected in the very early stage of esophageal, colon, breast, prostate carcinomas etc.
Given that pseudo-positive ratio of anti-p53 antibody is less than 5% in the healthy population, the detection of anti-mutant p53 IgG antibody holds much promising.
I would like to know your opinion on this useful marker.
Thank you in advance!
I would like to add that anti-p53 antibodies have been reported in other human diseases (other than cancers) such as auto-inflammatory and autoimmune diseases. Therefore, reducing its clinical usefulness.
An anti-p53 (mutant) antibody response can be observed in some carcinomas as you state, however, I do not think that it can be used as a marker of MRD in serum and its utility must be greatly uncertain ! As mentioned earlier, apart from cancer, antibodies to mutant p53 protein can be observed in autoimmune/autoinflammatory disorders, where DNA-damage response is taking place because of autoimmune-mediated normal tissue destruction.
Moreover, detection of mutant P53-bearing cells in the circulation by RT-PCR would be possible in the case that the primary tumor or metastases are carrying a mutant P53 allele. Moreover circulating tumor DNA (ctDNA) release by tumor cells undergoing apoptosis carrying a mutant P53 gene could be detected by PCR (liquid biopsy).
Are we talking about circulating tumour cells or residual tumour in tissue. Not all tumours are p53 positive . Circulating tumour cancer cells could probably be demonstrated using a Cytokeratin marker as blood cells are usually negative. In tissue its a bit more complex but detection of p53 in a serous carcinoma of ovary or endometrium is probably a diagnostic marker. Other tumours will have more specific markers in most cases eg GATA3 breast carcinoma etc although recognition of malignancy necessary.
Antibody selection would be difficult, 1st one may recognize mutant p53, but the 2nd one may not catch neither mutant nor wild p53.
Instead of western, you may choose RT-PCR. Specific primers may inform you in a better way.
Sincerely,
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology
- Biomolecules
- Nucleic Acids
- RNA